44 related articles for article (PubMed ID: 15075363)
1. Targeting neoantigens to APC-surface molecules improves the immunogenicity and anti-tumor efficacy of a DNA cancer vaccine.
Barrio-Calvo M; Kofoed SV; Holste SC; Sørensen AB; Viborg N; Kringelum JV; Kleine-Kohlbrecher D; Steenmans CS; Thygesen CB; Rønø B; Friis S
Front Immunol; 2023; 14():1234912. PubMed ID: 37720215
[TBL] [Abstract][Full Text] [Related]
2. A DNA Vaccine That Encodes an Antigen-Presenting Cell-Specific Heterodimeric Protein Protects against Cancer and Influenza.
Braathen R; Spång HCL; Hinke DM; Blazevski J; Bobic S; Fossum E; Bogen B
Mol Ther Methods Clin Dev; 2020 Jun; 17():378-392. PubMed ID: 32128342
[TBL] [Abstract][Full Text] [Related]
3. A DNA Vaccine That Targets Hemagglutinin to Antigen-Presenting Cells Protects Mice against H7 Influenza.
Andersen TK; Zhou F; Cox R; Bogen B; Grødeland G
J Virol; 2017 Dec; 91(23):. PubMed ID: 28931687
[TBL] [Abstract][Full Text] [Related]
4. Chemokines as Cancer Vaccine Adjuvants.
Bobanga ID; Petrosiute A; Huang AY
Vaccines (Basel); 2013 Dec; 1(4):444-62. PubMed ID: 24967094
[TBL] [Abstract][Full Text] [Related]
5. Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early time.
Vemula SV; Amen O; Katz JM; Donis R; Sambhara S; Mittal SK
Virus Res; 2013 Dec; 178(2):398-403. PubMed ID: 24051000
[TBL] [Abstract][Full Text] [Related]
6. Adenoviral vector expressing murine β-defensin 2 enhances immunogenicity of an adenoviral vector based H5N1 influenza vaccine in aged mice.
Vemula SV; Pandey A; Singh N; Katz JM; Donis R; Sambhara S; Mittal SK
Virus Res; 2013 Oct; 177(1):55-61. PubMed ID: 23892144
[TBL] [Abstract][Full Text] [Related]
7. Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells.
Fredriksen AB; Sandlie I; Bogen B
Front Oncol; 2012; 2():154. PubMed ID: 23115759
[TBL] [Abstract][Full Text] [Related]
8. Heterodimeric barnase-barstar vaccine molecules: influence of one versus two targeting units specific for antigen presenting cells.
Spång HC; Braathen R; Bogen B
PLoS One; 2012; 7(9):e45393. PubMed ID: 23028981
[TBL] [Abstract][Full Text] [Related]
9. DNA immunization with HBsAg-based particles expressing a B cell epitope of amyloid β-peptide attenuates disease progression and prolongs survival in a mouse model of Alzheimer's disease.
Olkhanud PB; Mughal M; Ayukawa K; Malchinkhuu E; Bodogai M; Feldman N; Rothman S; Lee JH; Chigurupati S; Okun E; Nagashima K; Mattson MP; Biragyn A
Vaccine; 2012 Feb; 30(9):1650-8. PubMed ID: 22248819
[TBL] [Abstract][Full Text] [Related]
10. Induction of immune tolerance in asthmatic mice by vaccination with DNA encoding an allergen-cytotoxic T lymphocyte-associated antigen 4 combination.
Zhang F; Huang G; Hu B; Song Y; Shi Y
Clin Vaccine Immunol; 2011 May; 18(5):807-14. PubMed ID: 21346053
[TBL] [Abstract][Full Text] [Related]
11. CCR4-expressing T cell tumors can be specifically controlled via delivery of toxins to chemokine receptors.
Baatar D; Olkhanud P; Newton D; Sumitomo K; Biragyn A
J Immunol; 2007 Aug; 179(3):1996-2004. PubMed ID: 17641067
[TBL] [Abstract][Full Text] [Related]
12. Tumor-associated embryonic antigen-expressing vaccines that target CCR6 elicit potent CD8+ T cell-mediated protective and therapeutic antitumor immunity.
Biragyn A; Schiavo R; Olkhanud P; Sumitomo K; King A; McCain M; Indig FE; Almanzar G; Baatar D
J Immunol; 2007 Jul; 179(2):1381-8. PubMed ID: 17617631
[TBL] [Abstract][Full Text] [Related]
13. Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses.
Schiavo R; Baatar D; Olkhanud P; Indig FE; Restifo N; Taub D; Biragyn A
Blood; 2006 Jun; 107(12):4597-605. PubMed ID: 16514063
[TBL] [Abstract][Full Text] [Related]
14. Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis.
Ruffini PA; Biragyn A; Coscia M; Harvey LK; Cha SC; Bogen B; Kwak LW
J Leukoc Biol; 2004 Jul; 76(1):77-85. PubMed ID: 15075363
[TBL] [Abstract][Full Text] [Related]
15. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity.
Biragyn A; Tani K; Grimm MC; Weeks S; Kwak LW
Nat Biotechnol; 1999 Mar; 17(3):253-8. PubMed ID: 10096292
[TBL] [Abstract][Full Text] [Related]
16. Immunity against breast cancer by TERT DNA vaccine primed with chemokine CCL21.
Yamano T; Kaneda Y; Hiramatsu SH; Huang S; Tran AN; Giuliano AE; Hoon DS
Cancer Gene Ther; 2007 May; 14(5):451-9. PubMed ID: 17318199
[TBL] [Abstract][Full Text] [Related]
17. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells.
Fredriksen AB; Sandlie I; Bogen B
Mol Ther; 2006 Apr; 13(4):776-85. PubMed ID: 16414309
[TBL] [Abstract][Full Text] [Related]
18. B-cell malignancies as a model for cancer vaccines: from prototype protein to next generation genetic chemokine fusions.
Biragyn A; Kwak LW
Immunol Rev; 1999 Aug; 170():115-26. PubMed ID: 10566146
[TBL] [Abstract][Full Text] [Related]
19. Viral vectors for gene transfer into antigen presenting cells.
Monahan SJ; Salgaller ML
Curr Opin Mol Ther; 1999 Oct; 1(5):558-64. PubMed ID: 11249662
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
